About Us

About ACTRIS

ACTRIS was established in April 2020 to meet the increasing clinical demand for cellular therapeutics to treat various life-threatening diseases.

Our vision is to be the national and regional Centre of Excellence for facilitating discovery, process development, and manufacturing of cellular-based therapeutics across the broad spectrum of immunotherapy and regenerative medicine, encompassing both investigational and clinical-use products for Singapore.

Through its specialised infrastructure and skilled workforce, ACTRIS aims to promote and support the entire value chain of the cell therapy ecosystem by enabling translational research and development, manufacturing, clinical service provision, and commercialisation across the healthcare, academic and industrial sectors.

In addition, ACTRIS will also provide value-added services such as workforce training, regulatory support, and the standardisation of ancillary materials and product testing pertaining to the delivery of cellular therapy to patients.

ACTRIS is a programme of the Consortium for Clinical Research and Innovation, Singapore (CRIS) and supported by the Singapore Ministry of Health for its set-up and through the National Medical Research Council Office, MOH Holdings Pte Ltd under the NMRC RIE2025 ACTRIS Funding Initiative (MOH-001528).

Our Mission

• To spearhead quality manufacturing of cellular-based therapeutics & develop cell therapy services.

• To support and foster collaboration in research & development within cell therapy ecosystem.

• To train and educate next generation of scientists and clinicians in cellular-based therapy.

Our Vision

• To be the national and regional Centre of Excellence for facilitating discovery, process development and manufacturing of cellular-based therapeutics.

Content in this section